FDA launches safety study of mifepristone amid access fight

The Food and Drug Administration has launched a safety study of mifepristone that could affect where patients get the drug, how doctors prescribe it and whether telehealth access survives the next round of legal and regulatory fights nationwide. The review, described as retrospective and involving hundreds of thousands of cases, arrives as abortion access remains deeply unsettled across the United States.

The timing matters because mifepristone is no longer a niche drug. FDA records say about 7.5 million women in the United States had used it through the end of December 2024, and medication abortion now makes up a large share of abortions nationwide. Any move by federal regulators to tighten the rules could reach patients even in states where abortion remains legal, especially if prescribing is narrowed or mail delivery is disrupted.

The drug has been at the center of a long-running regulatory tug-of-war. The FDA first approved Mifeprex, the brand name for mifepristone, in September 2000 for medical termination of pregnancy through seven weeks gestation. In 2016, the agency extended that approval to ten weeks. Then, on January 3, 2023, the FDA approved a modification to the Mifepristone REMS Program that removed the in-person dispensing requirement and allowed telehealth and mail access.

That change was not only procedural. FDA materials say the REMS program is meant to mitigate the risk of serious complications, but the agency concluded in 2021 that the available data supported reducing the burden on the health care system while maintaining safety. Medical groups have relied on that same evidence to defend broad access. The American College of Obstetricians and Gynecologists says mifepristone is safe, effective and integral to care, with complications that are exceedingly rare, minor and most often easily treatable.

The safety study now comes as courts continue to shape access by jurisdiction. On May 14, 2026, the Supreme Court maintained mail access to mifepristone for now after lower-court restrictions threatened telehealth prescribing and shipping by mail. That leaves patients, clinicians and pharmacies in a holding pattern while the administrative review moves forward.

Supporters of the drug point to the scale of its use and the rarity of serious adverse outcomes. Medical organization summaries cite FDA adverse-event data showing 36 deaths among 7.4 million users from 2000 through 2024, noting those deaths were not necessarily causally linked to the drug. For abortion access advocates, the new study is about more than science: it is a federal pathway that could reshape access before any formal restriction is even announced.